Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC

NCT07567326 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Adebrelimab, Retlirafusp alfa, Recaticimab and chemotherapy

Sponsor

Peking University Cancer Hospital & Institute